| Literature DB >> 35683532 |
Ambar N Lugo Merly1, Lorena A Montalvo Toledo1, Guillermo A Requejo1, Alexander Meléndez1, Samuel Álvarez1, Andrés López1, Radames Ríos1, Victor M Villegas1, Armando L Oliver1.
Abstract
Endophthalmitis treatment consists of intravitreal antibiotics injections and, in selected circumstances, pars plana vitrectomy. However, severe or refractory cases may require an enucleation or evisceration (ENEV). Our study seeks to identify risk factors leading to enucleation or evisceration in patients with infectious endophthalmitis. A retrospective chart review of subjects with a clinical diagnosis of infectious endophthalmitis was undertaken. The affected eyes were stratified into groups: those that underwent ENEV and those in which the eyeball was preserved (EP). The groups were compared using statistical analyses. In total, 69 eyes diagnosed with infectious endophthalmitis were included in the study. There was a higher frequency of exogenous infectious endophthalmitis in the ENEV group versus the EP group. Postsurgical infectious endophthalmitis was lower in the ENEV than in the EP group. A visual acuity of no light perception was more common in the ENEV compared to the EP group. Panophthalmitis was more frequent in the ENEV versus the EP group. Our findings suggest that eyes with endophthalmitis presenting with a visual acuity of no light perception, panophthalmitis, or exogenous etiology have a higher risk of requiring ENEV. In addition, eyes with a postsurgical etiology may be at a lower risk of requiring ENEV.Entities:
Keywords: endophthalmitis; enucleation; evisceration; panophthalmitis
Year: 2022 PMID: 35683532 PMCID: PMC9181767 DOI: 10.3390/jcm11113145
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Demographic and Clinical Characteristics of Study Population.
| Number of patients (n) | 69 |
| Median age (y) | 70 (range, 10–95) |
| Gender (%) | |
| Female | 40.58% |
| Male | 59.42% |
| Past Medical History (%) | |
| Diabetes | 62.32% |
| Immunosuppressed state | 4.35% |
| IVDA history | 2.90% |
| Systemic surgery | 2.90% |
| Eye-Specific Characteristics at Presentation (%) | |
| Unilateral | 100% |
| Right eye affected | 55.07% |
| Left eye affected | 44.93% |
| Visual Acuity at Presentation (%) | |
| NLP | 24.64% |
| LP | 27.54% |
| HM | 21.74% |
| CF or more | 21.74% |
| Unable to assess | 4.35% |
| Etiology (%) | |
| Postsurgical | 37.68% |
| Exogenous | 33.33% |
| Post-traumatic | 14.49% |
| Endogenous | 13.04% |
| Unknown etiology | 1.45% |
| Presence of panophthalmitis (%) | |
| Panophthalmitis | 20.29% |
| Outcome (%) | |
| Evisceration or enucleation | 46.38% |
| Eye conservation | 53.62% |
IVDA: intravenous drug abuse; OD: right eye; OS: left eye; NLP: no light perception; LP: light perception; HM: hand motion; CF: counting fingers.
Comparison of Characteristics of ENEV Group vs. EP Group.
| ENEV | EP | OR | 95% CI | ||
|---|---|---|---|---|---|
|
| 32 (46.38%) | 37 (53.62%) | |||
|
| |||||
|
| 71.84 | 65.6 | 0.82613–13.826 | 0.071 a | |
|
| 16 (50%) | 25 (67.57%) | 0.485 | 0.161–1.418 | 0.216 b |
|
| 16 (50%) | 12 (32.43%) | |||
|
| |||||
|
| 7 (21.88%) | 19 (51.35%) | 0.271 | 0.0783–0.848 | 0.023 c |
|
| 18 (56.25%) | 5 (13.51%) | 7.946 | 2.273–33.135 | 0.0005 c |
|
| 2 (6.25%) | 7 (18.92%) | 0.291 | 0.027–1.695 | 0.161 b |
|
| 5 (15.63%) | 5 (13.51%) | 1.182 | 0.244–5.738 | 1 b |
|
| |||||
|
| 19 (59.38%) | 24 (64.86%) | 0.794 | 0.267–2.352 | 0.836 b |
|
| 1 (3.13%) | 2 (5.41%) | 0.553 | 0.009–11.116 | 1 b |
|
| 1 (3.13%) | 1 (2.70%) | 1.098 | 0.014–88.88 | 1 b |
|
| |||||
|
| |||||
|
| 6 (18.75%) | 16 (43.24%) | 0.318 | 0.085–1.058 | 0.066 b |
|
| 24 (75.00%) | 20 (54.05%) | |||
|
| |||||
|
| 15 (46.88%) | 2 (5.41%) | 17.832 | 3.476–180.530 | 0.00003 b |
|
| 7 (21.88%) | 12 (32.43%) | 0.667 | 0.187–2.232 | 0.642 c |
|
| 4 (12.59%) | 11 (29.73%) | 0.383 | 0.0785–1.517 | 0.1497 b |
|
| 3 (9.38%) | 12 (32.43%) | 0.2453 | 0.0397–1.060 | 0.044 b |
|
| |||||
|
| 12 (37.50%) | 2 (5.41%) | 10.15 | 1.967–102.461 | 0.002 b |
|
| 20 (62.50%) | 35 (95.59%) | |||
|
| |||||
|
| 16 (50.00%) | 15 (40.54%) | 1.458 | 0.509–4.239 | 0.586 c |
|
| 16 (50.00%) | 14 (37.84%) | 1.631 | 0.567–4.784 | 0.4396 c |
|
| 0 (0.00%) | 1 (2.70%) | 0 | 0.000–45.063 | 1 b |
|
| 10 (31.25%) | 12 (32.43%) | 0.346 | 0.0273–2.701 | 0.3898 b |
|
| 5 (15.63%) | 2 (5.41%) | |||
OR: odds ratio; CI: confidence interval; IVDA: intravenous drug abuse, OD: right eye; OS: left eye; NLP: no light perception; LP: light perception; HM: hand motion; CF: counting fingers; EP: eye preserved. a Welch’s t-test. b Fisher’s exact test (for count data). c Pearson’s chi-square test.